Fragmented QRS: a marker of hypertensive heart disease? J Clin Hypertens (Greenwich) 2017 Sep;19(9):866-867.
Fragmented QRS complexes are a marker of myocardial fibrosis in hypertensive heart disease. Turk Kardiyol Dern Ars 2016 Oct;44(7):554-560.
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986 Feb;57(6):450-458.
Gender differences and electrocardiogram in left ventricular hypertrophy. Hypertension 1995 Feb;25(2):242-249.
The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991 Jul;266(2):231-236.
Influence of cigarette smoking on the electrocardiographic diagnosis of left ventricular hypertrophy in arterial hypertension. G Ital Cardiolo 1999 Jan;29(1):34-38.
Relative wall thickness is an independent predictor of left ventricular systolic and diastolic dysfunctions in essential hypertension. Hypertens Res 2001 Sep;24(5):493-499.
The septal bulge—an early echocardiographic sign in hypertensive heart disease. J Am Soc Hypertens 2016 Jan;10(1):70-80.
Tricuspid annular motion velocity as a differentiation index of hypertrophic cardiomyopathy from hypertensive heart disease. J Cardiol 2015 Jun;65(6):519-525.
Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue doppler ultrasonography. Circulation 2004 Dec;110(25):3808-3814.
Strain rate imaging differentiates hypertensive cardiac hypertrophy from physiologic cardiac hypertrophy (athlete's heart). J Am Soc Echocardiogr 2007 Feb;20(2):151-157.
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990 May;322(22):1561-1566.
Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999 Mar;317(3):168-175.
Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertns 2003 Nov;16(11 Pt 1):895-899.
; Losartan Intervention for End-Point Reduction Study Investigators. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for End-Point Reduction (LIFE) Study. Circulation 2003 Aug;108(6):684-690.
; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for End Point Reduction in hypertension (LIFE) study: a randomized trial against atenolol. Lancet 2002 Mar;359(9311):995-1003.
; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004 Nov;292(19):2343-2349.
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004 Nov;292(19):2350-2356.
High-resolution trans-thoracic real-time three-dimensional echocardiography: quantitation of cardiac volumes and function using semi-automatic border detection and comparison with cardiac magnetic resonance imaging. J Am Coll Cardiol 2004 Jun;43(11):2083-2090.
Multimodality imaging for left ventricular hypertrophy severity grading: a methodological review. J Cardiovasc Ultrasound 2016 Dec;24(4):257-267.
Quantitative assessment of regional left ventricular wall thickness and thickening using 16 multidetector-row computed tomography: comparison with cine magnetic resonance imaging. Radiat Med 2007 Apr;25(3):119-126.
The role of imaging in hypertensive heart disease. Int J Angiol 2014 Jun;23(2):85-92.